Feprazone

Summary

Feprazone (CHEMBL1452696) is an approved small molecule (ATC M02AA16); indicated across 3 conditions including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M02AA16 (+2 more)
• Indications: 3 conditions
• Chemistry: 320.4 Da · C20H20N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1452696
Name	Feprazone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	35455
ATC	M02AA16, M01AX18, M01AX68
Molecular formula	C20H20N2O2
Molecular weight	320.4
InChIKey	RBBWCVQDXDFISW-UHFFFAOYSA-N

SMILES: CC(=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C

IUPAC name: 4-(3-methylbut-2-enyl)-1,2-diphenylpyrazolidine-3,5-dione

Also known as: DA 2370, DA-2370, Feprazona, Feprazone, SID26758004, SID144205761, FEPRAZONE, SID170465969, feprazone

Patent coverage: 2,428 distinct patent families (9,738 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Nuclear receptor ROR-gamma, Prelamin-A/C, Prostaglandin G/H synthase 1, Bile salt export pump.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS1	6.58	AC50	260	nM	CHEMBL_ACT_25205277

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).